Xultophy (insulin degludec/liraglutide) effectiveness evaluated in real-world European adults with Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disorder requiring effective glucose management. Current treatments often struggle with sustained glycemic control and weight management, leading to complications. Insulin degludec provides basal insulin coverage, while liraglutide, a GLP-1R agonist, enhances glucose-dependent insulin secretion, suppresses glucagon, and promotes satiety. The fixed-ratio combination Xultophy aims to simplify treatment and improve outcomes by leveraging both mechanisms, addressing the need for comprehensive glycemic and weight control in a single injection.

This was a multi-center, prospective, open-label, single-arm, non-interventional post-marketing surveillance study conducted in Europe. It aimed to investigate the real-world effectiveness of Xultophy® (insulin degludec/liraglutide) in adults with Type 2 Diabetes Mellitus. The study design is observational, focusing on routine clinical practice rather than a controlled trial. No specific dose, route, frequency, duration, or primary endpoint are mentioned for this study, nor is a sample size.

The provided abstract does not contain specific findings, numerical results, p-values, or fold-changes. This study's aim was to investigate the effectiveness of Xultophy® in a real-world setting, but the results of this investigation are not detailed in the available text.